Drugs & TargetsFree FDA expands indications for AZ’s Lynparza, making it first treatment for breast cancer with BRCA mutation January 12, 2018Vol.44 No.02
Drugs & TargetsFree FDA approves Cabometyx for previously untreated advanced renal cell carcinoma January 05, 2018Vol.44 No.01
Drugs & TargetsFree FDA approves Pfizer’s Bosulif (bosutinib) for newly-diagnosed Ph+ CML January 05, 2018Vol.44 No.01
Drugs & TargetsFree FDA approves Xgeva for prevention of skeletal-related events in multiple myeloma January 05, 2018Vol.44 No.01
Drugs & TargetsFree Kisqali receives breakthrough designation for HR+/HER2- breast cancer January 05, 2018Vol.44 No.01
Drugs & TargetsFree FDA accepts sBLA, grants priority review for Adcetris January 05, 2018Vol.44 No.01
Drugs & TargetsFree FDA grants breakthrough designation for Avelumab in combination with Inlyta in RCC January 05, 2018Vol.44 No.01
Drugs & TargetsFree FDA grants orphan drug designation to Aptose Biosciences for CG’806 in AML January 05, 2018Vol.44 No.01
Drugs & TargetsFree FDA accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated NSCLC January 05, 2018Vol.44 No.01
